Research programme: ocular inflammation therapy - SantenAlternative Names: Nova 22038
Latest Information Update: 29 May 2013
Price : *
At a glance
- Originator Novagali Pharma
- Developer Santen S.A.S.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ocular inflammation